JNJ:NYSEJohnson & Johnson Analysis

Johnson & Johnson is trading at $242.81, just below its 20‑day SMA of $243.81 and comfortably above the 50‑day SMA, confirming a short‑term bullish bias. The RSI of 57 indicates the stock is not overbought, while the MACD histogram remains negative, suggesting lingering bearish momentum that could temper upside. Volume has been trending down, but the overall market sentiment is extremely positive (Fear & Greed Index at “Extreme Greed”), and the stock is riding a wave of momentum highlighted in recent news, including its inclusion among the top defensive dividend stocks and an analyst price target raise to $253. Fundamentals remain solid: revenue grew 9.1% YoY, operating margin sits at 24%, ROE is a robust 35%, and the dividend yield of 2.16% is supported by a modest 46.6% payout ratio. However, the discounted cash‑flow model values JNJ at roughly $129, implying the market price is significantly overvalued, a view reinforced by a modest -2.3% upside/downside metric. Low beta (~0.06) and a 30‑day volatility of 16% point to relatively stable price swings, while the healthcare sector’s defensive nature cushions sector‑specific risk.
Overall, the stock offers a blend of value and growth attributes with a strong dividend profile, but investors should be mindful of the valuation premium and the mixed technical signals. The consensus “Buy” recommendation aligns with the positive earnings momentum and dividend appeal, yet a cautious stance may be prudent given the overvaluation relative to intrinsic estimates.